Cytokine Therapy: Interferon and Interleukin — Where They Stand Now

They are cytokines — signalling proteins the immune system already uses to talk to itself — given as medicine, in far larger amounts than the body would ever make. Interferons and interleukins were the first immunotherapies that worked in cancer, from the late 1980s onward. They were also the first to show what a whole-body immune push costs the person receiving it.

The idea behind them is old and intuitive. If the immune system can sometimes control a cancer on its own, then supplying the molecules it uses to raise an alarm should make that happen more often. Interferon alfa was the alarm signal borrowed from the body's antiviral response. Interleukin-2 was the growth signal that makes T cells multiply.

It worked — in a minority of patients, and at a cost. That is the honest summary. It is also why this page exists. Most families who ask about interferon are not researching something they have been offered. They are remembering what happened to a father, an uncle or a neighbour twenty-five years ago, and asking whether the immunotherapy now on the table is the same thing. It is not, and the reason it is not is most of the story of the last fifteen years in cancer immunotherapy.

Categories and guideline positions summarised from NCCN and ESMO patient-education material, current as of August 2026. Classes and mechanisms only — no products are named or compared here. Whether any of this applies to you is a question for your treating oncologist, with your reports in front of them.

Side effects are described here as classes of problem, at the level a patient-education page can responsibly cover. Your own risk depends on the medicine, the dose, your organ function and what else you are taking, and only your treating team can set that out for you.

• In myeloproliferative neoplasms — pegylated interferon alfa is an established option in polycythaemia vera and essential thrombocythaemia, and is one of the few options considered acceptable during pregnancy. This is haematology practice, not solid-tumour oncology.
• In hairy cell leukaemia — interferon alfa is still recognised in selected situations, although it is usually not the first treatment chosen today.
• Inside cell-therapy protocols — interleukin-2 is given after an infusion of expanded tumour-infiltrating lymphocytes, to keep those cells alive and dividing. See Tumour-Infiltrating Lymphocyte (TIL) Therapy. CION does not provide CAR-T or any cell therapy product; that page is orientation for a referral, not an offer.
• At specialist centres, for a few patients — high-dose interleukin-2 is still listed for carefully selected metastatic melanoma and kidney cancer patients who are fit enough, where intensive-care backup exists. Very few centres in India are set up for it.
• Re-engineered, in research — modified interleukins, interleukin-15 agonists and cytokines delivered locally rather than systemically are an active research area. Some oncolytic viruses are built to release a cytokine inside the tumour so the signal is concentrated where it is needed — see Oncolytic Virus Therapy: Using a Virus to Attack Cancer.

Research described here is research. Nothing in that last point is treatment you can ask for outside a registered clinical trial, and this page does not recruit for one. If a trial interests you, raise it with your treating oncologist — enrolment always goes through your own team.

1. 1

   The target became specific

   Interferon and interleukin push the entire immune system. Checkpoint inhibitors act on one defined interaction between a T cell and a tumour cell. Narrower action, narrower toxicity. Checkpoint Inhibitors: How Releasing the Brakes on Immunity Works sets out the mechanism.

2. 2

   The setting changed

   High-dose interleukin-2 needed an inpatient bed and intensive-care backup. The newer classes are given in a day-care chair, over roughly thirty to sixty minutes, every two to six weeks.

3. 3

   More people could actually receive it

   Age, heart function and kidney function ruled many patients out of high-dose cytokines altogether. A far larger group can at least be considered for a day-care infusion, including older patients with other health conditions.

4. 4

   Testing began to guide the choice

   Cytokine treatment had no companion test at all. Newer immunotherapy is selected with biomarker results such as PD-L1 expression or mismatch-repair status, so fewer people are exposed to a treatment unlikely to help them.

5. 5

   The side effects moved, they did not vanish

   Immune-related inflammation of the bowel, lungs, liver, thyroid and other glands took the place of the flu-like syndrome. It is far more manageable when reported early, which is why immunotherapy patients are told to report new symptoms rather than wait for the next visit.

Almost certainly not. What is likely to be offered today is a different class of medicine, given as a short day-care infusion, with a different pattern of side effects. What does carry across is the principle: the treatment acts on your immune system, not directly on the tumour.

The memory is vivid for a reason. People who watched a relative on high-dose interferon remember the fevers, the weight coming off, the appetite going, and a change in personality that the family often had no words for at the time. None of that was exaggeration. It was documented, expected, and part of why the treatment was so difficult to complete.

What is different now is the schedule and the setting. Immunotherapy at CION is administered as day care at our centres — you come in, the infusion runs, and you go home the same day. Response assessment usually involves a PET-CT, which is coordinated at partner imaging centres rather than owned by us. Between cycles, most people are at home and managing their usual routine.

What is not different is that this is a real medicine with real risks. Immune-related side effects can be serious, and a few of them are urgent. The rule that matters is simple: tell any doctor who sees you that you are on immunotherapy, and report new bowel, breathing, chest or energy symptoms early rather than waiting to see whether they settle.

One more thing worth saying plainly, because it is often left out: most patients in India are not candidates for immunotherapy at all. Eligibility depends on the cancer type, the stage, biomarker results and general fitness, and for a great many people the honest answer is that a different treatment is the right one. The immunotherapy hub covers eligibility, biomarker testing, day-care administration and cost in more detail.

• Checkpoint Inhibitors: How Releasing the Brakes on Immunity Works — the class that took over most of the ground interferon and interleukin once held, and why its mechanism is narrower.
• Tumour-Infiltrating Lymphocyte (TIL) Therapy — the cell-therapy approach in which interleukin-2 is still given, as support for the infused cells. Referral orientation only; CION does not provide cell therapy.
• Oncolytic Virus Therapy: Using a Virus to Attack Cancer — where cytokines are being delivered locally inside the tumour instead of flooding the whole body.
• Immunotherapy at CION Cancer Clinics — the hub page, covering who is eligible, biomarker testing, how day-care administration works and what it costs.

This page is general information and does not replace a consultation. It names drug classes and mechanisms only, not products, and makes no comparison of efficacy between products. Guideline positions are summarised from NCCN and ESMO patient-education material as of August 2026. Treatment decisions must be made with your treating oncologist.

Families often arrive carrying a memory of interferon

A relative treated in the 1990s leaves a strong impression. Our team will explain what has changed, what has not, and what your own treatment would actually involve.